Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.8 USD | +3.53% | -3.40% | -17.94% |
Financials (USD)
Sales 2024 * | 1.03M | Sales 2025 * | 800K | Capitalization | 26.04M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -46M | EV / Sales 2024 * | 25.2 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 32.6 x |
P/E ratio 2024 * |
-0.82
x | P/E ratio 2025 * |
-0.92
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.7% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | +3.53% | ||
1 week | -3.40% | ||
Current month | -4.45% | ||
1 month | +0.63% | ||
3 months | -7.37% | ||
6 months | +27.28% | ||
Current year | -17.94% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 68 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-05 | 8.8 | +6.02% | 10,420 |
24-06-04 | 8.3 | -5.47% | 9,491 |
24-06-03 | 8.78 | -4.67% | 4,029 |
24-05-31 | 9.21 | +1.21% | 4,220 |
24-05-30 | 9.1 | -0.11% | 2,143 |
Delayed Quote Nasdaq, June 05, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-17.94% | 26.04M | |
+55.70% | 59.34B | |
+43.17% | 40.24B | |
-5.39% | 39.88B | |
-5.56% | 28.55B | |
+16.46% | 27.26B | |
-20.56% | 19.23B | |
+33.03% | 12.61B | |
+2.72% | 12.49B | |
+25.85% | 12.28B |
- Stock Market
- Equities
- ONCT Stock